(market cap was way above 500M before the drop so idk if allowed)
Reading the actual results (https://finance.yahoo.com/sectors/healthcare/articles/tovecimig-demonstrates-statistically-significant-benefit-113000084.html) it looks like the drug works, but “failed” in an secondary endpoint because of high crossover with other med, which is not entirely bad
Overall this 65% drop feels like an overreaction, did an LLM just read “failed” once in the release and decided to dump the stock?
Posted by flight212121
1 Comment
May be not. If algo read it wrongly initially and sold it, the savy analyst would have bought it now if there is a potential after deep dive. So, you can’t blame LLM here, imo.